|
|
Volumn 12, Issue 6, 2007, Pages 170-
|
|
Rosiglitazone increased heart failure but did not differ from metformin plus sulphonylurea for other CV outcomes at interim analysis
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
GLIBENCLAMIDE;
GLICLAZIDE;
GLIMEPIRIDE;
HEMOGLOBIN A1C;
INSULIN;
METFORMIN;
ROSIGLITAZONE;
SULFONYLUREA;
ADD ON THERAPY;
CARDIOVASCULAR DISEASE;
CARDIOVASCULAR EFFECT;
CARDIOVASCULAR RISK;
CAUSE OF DEATH;
CEREBROVASCULAR ACCIDENT;
CLINICAL TRIAL;
CONGESTIVE HEART FAILURE;
DRUG MEGADOSE;
DRUG SUBSTITUTION;
DRUG WITHDRAWAL;
HEART DEATH;
HEART FAILURE;
HEART INFARCTION;
HOSPITAL ADMISSION;
HUMAN;
NON INSULIN DEPENDENT DIABETES MELLITUS;
OUTCOME ASSESSMENT;
RISK ASSESSMENT;
RISK FACTOR;
SHORT SURVEY;
|
|
EID: 38049024428
PISSN: 13565524
EISSN: None
Source Type: Journal
DOI: 10.1136/ebm.12.6.170 Document Type: Short Survey |
|
Times cited : (2)
|
|
References (0)
|